Nanobac Pharmaceuticals, Inc. Retains Clinical Research Organization for Biomarker Development.

Business Editors/Health/Medical Writers

TAMPA, Fla.--(BUSINESS WIRE)--Feb. 6, 2004

Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP) ("NANOBAC" or "The Company") announced that it has retained DIAGNOSTIC ONCOLOGY CRO, Inc. (DOCRO) to assist with the development, validation, including FDA clinical trials, and commercialization of NANOBAC's laboratory tests detecting the presence of, or exposure to, Nanobacterium sanguineum.

"We are extremely excited to be working with what we believe to be the best clinical research organization in the country," said Alex Edwards, Nanobac's CEO and President. "Further, this represents the next step toward identifying a biomarker that is potentially indicative of an infectious process that is the root cause of pathological calcification."

DOCRO is the leading contract research organization (CRO) focused on the development, clinical validation, FDA registration, and commercialization of biomarker technologies for the in vitro diagnostic (IVD) industry.

DOCRO has a diverse and extensive experience with a wide variety of biomarkers and other proteomic or genomic diagnostic tests, of which, many are now standard of care biomarkers in the field of oncology, cardiology and infectious disease. "DOCRO is extremely excited to be working with NANOBAC on this important technology. We believe DOCRO provides NANOBAC with a knowledgeable and experienced partner to help navigate the nanobacterium technology through the intricate process of technology development, clinical trials, FDA submission and, ultimately, approval," commented Thomas Soriano, President and CEO of DOCRO. During the past five years, DOCRO has participated in more than 70 biomarker clinical trials resulting in FDA approval.

DOCRO (www.docro.com) is an internationally recognized Connecticut-based company whose business centers on the development, validation, FDA registration, and commercialization of biomarker technologies emerging from genomic and proteomic discovery. In addition to the contract research services, DOCRO also provides standard of care and novel laboratory testing services to pharmaceutical companies and to other clinical research organizations through its subsidiary, Orion Laboratory. The combined company offers a powerful portfolio of contract research and related services meeting the needs of companies developing biomarkers and biomarker-targeted therapies.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For more information, please visit our website at www.nanobaclabs.com or contact us at [e-mail].

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which might cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report, these statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.